Mineralys Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Mineralys Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $172.92 million for the year ending 2025.

  • Mineralys Therapeutics, Inc. showed an increase of +51.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 97.2%.
  • Historical annual values: Fiscal year 2025: $172.92 million | Fiscal year 2024: $114.09 million | Fiscal year 2023: $49.30 million | Fiscal year 2022: $87.70 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: